Posted in Canada, Competition, Copyright, Innovation, IP Reform, Regulatory Policy, Trademarks
Comments 2

The Myriad Genetics gene patenting saga has officially shaped international jurisprudence, with the Federal Court of Australia upholding the patents for BRCA1 and BRCA2. In Cancer Voices Australia v. Myriad Genetics, NSD643/2010, Federal Court of Australia (Sydney), the first Australian case to deal with the issue of gene patents, the Court took a similarly liberal [...]

Posted in Access to Medicines, Competition, Human Rights, IP, Patent Practice, Patentability, Patents
Comment: 1

The Intellectual Property Institute of Canada (IPIC) and IP Osgoode are delighted to announce our 2013 Canadian writing challenge in intellectual property law. We are excited to be running our fifth annual writing challenge.  Our goal is to further enhance thoughtful and well-researched intellectual property public policy scholarship and discussion. We encourage a broad range [...]

Posted in Announcements, Competition, events, Feature Post, IP
Comments: 0

The long battle in the American courts over Myriad Genetics’ patents of BRCA1 and BRCA2, the primary diagnostic genes for hereditary breast and ovarian cancer has been well-documented in the IPilogue (see coverage by Beatrice yesterday as well as previous posts here, here, and here). Now, Myriad is poised to defend their patents at the Supreme Court for a second time, with [...]

Posted in Blogs, Commercialization, Competition, European Union, Human Rights, Innovation, Patent Practice, Patentability, Patents, Regulatory Policy, Trade Secrets, US
Comments 2